Role of Specific B-Cell Receptor Antigens in Lymphomagenesis

The B-cell receptor (BCR) signaling pathway is a crucial pathway of B cells, both for their survival and for antigen-mediated activation, proliferation and differentiation. Its activation is also critical for the genesis of many lymphoma types. BCR-mediated lymphoma proliferation may be caused by activating BCR-pathway mutations and/or by active or tonic stimulation of the BCR. BCRs of lymphomas have frequently been described as polyreactive. In this review, the role of specific target antigens of the BCRs of lymphomas is highlighted. These antigens have been found to be restricted to specific lymphoma entities. The antigens can be of infectious origin, such as H. pylori in gastric MALT lymphoma or RpoC of M. catarrhalis in nodular lymphocyte predominant Hodgkin lymphoma, or they are autoantigens. Examples of such autoantigens are the BCR itself in chronic lymphocytic leukemia, LRPAP1 in mantle cell lymphoma, hyper-N-glycosylated SAMD14/neurabin-I in primary central nervous system lymphoma, hypo-phosphorylated ARS2 in diffuse large B-cell lymphoma, and hyper-phosphorylated SLP2, sumoylated HSP90 or saposin C in plasma cell dyscrasia. Notably, atypical posttranslational modifications are often responsible for the immunogenicity of many autoantigens. Possible therapeutic approaches evolving from these specific antigens are discussed.

[1]  A. Rosenwald,et al.  Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma , 2020, Haematologica.

[2]  Á. Illés,et al.  ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Pfreundschuh,et al.  Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma , 2020, Nature Communications.

[4]  J. Byrd,et al.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial , 2020, The Lancet.

[5]  J. Cyster,et al.  The transcription factor Hhex cooperates with the corepressor Tle3 to promote memory B cell development , 2020, bioRxiv.

[6]  A. Salar,et al.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Dolca Thomas,et al.  Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia , 2019, Blood.

[8]  A. Kater,et al.  A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation , 2019, Blood.

[9]  S. Tyekucheva,et al.  LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL , 2019, Blood.

[10]  T. Shanafelt,et al.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. , 2019, The New England journal of medicine.

[11]  Jing Wang,et al.  Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro , 2019, Experimental and Molecular Therapeutics.

[12]  J. Edwards,et al.  DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS , 2019, Hematological Oncology.

[13]  L. Staudt,et al.  Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Arnold,et al.  Primary Analysis of a Randomized Phase II Study to Evaluate the Efficacy and Safety of Evobrutinib, a BTK Inhibitor, in Patients with Relapsing MS , 2019 .

[15]  M. Trepel,et al.  Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane , 2019, Nature Communications.

[16]  A. Rosenwald,et al.  Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. , 2018, Blood.

[17]  L. Staudt,et al.  Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma , 2018, Blood.

[18]  R. Siebert,et al.  Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma , 2018, Blood.

[19]  M. Pfreundschuh,et al.  Saposin C is a frequent target of paraproteins in Gaucher disease‐associated MGUS/multiple myeloma , 2018, British journal of haematology.

[20]  Lisa L. Smith,et al.  The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. , 2018, Cancer discovery.

[21]  M. Pfreundschuh,et al.  LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting , 2018, Leukemia.

[22]  L. Staudt,et al.  A Multiprotein Supercomplex Controlling Oncogenic Signaling in Lymphoma , 2018, Nature.

[23]  M. Dimopoulos,et al.  Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia , 2018, The New England journal of medicine.

[24]  Alexander V Penson,et al.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. , 2018, Blood.

[25]  Asher Mullard FDA approves first-in-class SYK inhibitor , 2018, Nature Reviews Drug Discovery.

[26]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[27]  D. Hose,et al.  Antigen-mediated regulation in monoclonal gammopathies and myeloma. , 2018, JCI insight.

[28]  M. Reth,et al.  Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells , 2018, The EMBO journal.

[29]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[30]  S. Lade,et al.  Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma , 2018, The New England journal of medicine.

[31]  B. Kyewski,et al.  T cells specific for post-translational modifications escape intrathymic tolerance induction , 2018, Nature Communications.

[32]  O. Griffith,et al.  Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. , 2018, Blood.

[33]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[34]  A. Rickinson,et al.  Epstein–Barr virus-associated lymphomas , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[35]  Michael R. Green,et al.  Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. , 2017, Blood.

[36]  I. Flinn,et al.  Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma , 2016 .

[37]  C. Flowers,et al.  Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study , 2016 .

[38]  E. Giné,et al.  Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. , 2016, Cancer cell.

[39]  F. Toledo,et al.  First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  L. Pasqualucci,et al.  The genetics of nodal marginal zone lymphoma. , 2016, Blood.

[41]  W. Klapper,et al.  Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma , 2016, Haematologica.

[42]  A. Lanzavecchia,et al.  Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease , 2016, Science.

[43]  W. Wilson,et al.  Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. , 2016, Blood.

[44]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[45]  M. Słabicki,et al.  Elucidation of tonic and activated B-cell receptor signaling in Burkitt’s lymphoma provides insights into regulation of cell survival , 2016, Proceedings of the National Academy of Sciences.

[46]  Ronald Levy,et al.  Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies , 2016, Proceedings of the National Academy of Sciences.

[47]  Nibedita Bandyopadhyay,et al.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.

[48]  M. Dhodapkar,et al.  Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. , 2016, The New England journal of medicine.

[49]  R. Kamble,et al.  Complete Resolution of Extensive Chronic Graft-Versus-Host Disease with Ibrutinib , 2015 .

[50]  L. Staudt,et al.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens , 2015, Proceedings of the National Academy of Sciences.

[51]  M. Pfreundschuh,et al.  CD4+ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia , 2015, International journal of cancer.

[52]  M. Nussenzweig,et al.  Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma , 2015, Cell.

[53]  E. Nordhoff,et al.  Proteins Lymphoma B Cell Receptors Recognize Cns Primary Central Nervous System (cns) , 2022 .

[54]  A. Ferreri,et al.  High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[56]  Jeffrey A Jones,et al.  Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. , 2015, Blood.

[57]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[58]  D. Rawlings,et al.  B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. , 2015, Current opinion in immunology.

[59]  A. Zelenetz,et al.  Management of adverse events associated with idelalisib treatment: expert panel opinion , 2015, Leukemia & lymphoma.

[60]  M. Pfreundschuh,et al.  Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor. , 2015, The Journal of clinical investigation.

[61]  N. Bottini,et al.  PTPN22: the archetypal non-HLA autoimmunity gene , 2014, Nature Reviews Rheumatology.

[62]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[63]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[64]  J. Byrd,et al.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). , 2014, Blood.

[65]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[66]  Yuchen Jiao,et al.  Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer , 2014, Science.

[67]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[68]  M. Stetler-Stevenson,et al.  Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. , 2013, Leukemia research.

[69]  R. Bende,et al.  A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi , 2013, The Journal of experimental medicine.

[70]  R. Mertelsmann,et al.  CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. , 2013, Blood.

[71]  M. Pfreundschuh,et al.  Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. , 2012, Blood.

[72]  R. Spang,et al.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.

[73]  R. Siebert,et al.  Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma , 2012, Acta Neuropathologica.

[74]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[75]  S. Pileri,et al.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development , 2012, The Journal of experimental medicine.

[76]  M. Minden,et al.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling , 2012, Nature.

[77]  F. Cavalli,et al.  Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  C. Vachon,et al.  Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. , 2012, Blood.

[79]  K. Stamatopoulos,et al.  Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity , 2012, Leukemia.

[80]  W. Wilson,et al.  How I treat HIV-associated lymphoma. , 2012, Blood.

[81]  Emanuela M. Ghia,et al.  Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. , 2012, Blood.

[82]  J. Kutok,et al.  Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model , 2012, Cell.

[83]  H. Doyle,et al.  Autoantigenesis: the evolution of protein modifications in autoimmune disease. , 2012, Current opinion in immunology.

[84]  Govind Bhagat,et al.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.

[85]  C. Klein,et al.  IL‐10 and IL‐10 receptor defects in humans , 2011, Annals of the New York Academy of Sciences.

[86]  R. Siebert,et al.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma , 2011, Acta Neuropathologica.

[87]  M. Pfreundschuh,et al.  Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A. , 2011, Blood.

[88]  A. Rosenwald,et al.  Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. , 2011, Blood.

[89]  K. Rajewsky,et al.  Efficient generation of B lymphocytes by recognition of self‐antigens , 2011, European journal of immunology.

[90]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[91]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[92]  A. Tonevitsky,et al.  Design of Targeted B Cell Killing Agents , 2011, PloS one.

[93]  M. Ziepert,et al.  Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. , 2011, Blood.

[94]  M. Ziepert,et al.  Risk of Japanese carriers of hyperphosphorylated paratarg‐7, the first autosomal‐dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma , 2011, Cancer science.

[95]  P. Tosi,et al.  Lack of allelic exclusion by secondary rearrangements of tumour B‐cell receptor light chains in hairy cell leukaemia , 2011, Hematological oncology.

[96]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[97]  D. Markovitz,et al.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. , 2011, Arthritis and rheumatism.

[98]  M. Pfreundschuh,et al.  Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. , 2011, Journal of autoimmunity.

[99]  L. Liotta,et al.  Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. , 2011, Journal of proteome research.

[100]  H. Schlüter,et al.  Stereotypical Chronic Lymphocytic Leukemia B-Cell Receptors Recognize Survival Promoting Antigens on Stromal Cells , 2010, PloS one.

[101]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[102]  A. Ghaemmaghami,et al.  Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins , 2010, Proceedings of the National Academy of Sciences.

[103]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[104]  R. Bende,et al.  MALT lymphoma-derived rheumatoid factors are nonpolyreactive high-affinity antibodies. , 2010, Blood.

[105]  C. Liu,et al.  The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. , 2010, Immunity.

[106]  Weidong Zhou,et al.  Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. , 2010, Journal of proteome research.

[107]  N. Chiorazzi,et al.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. , 2010, Blood.

[108]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[109]  S. Falkow,et al.  Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. , 2010, Blood.

[110]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[111]  T. Veenstra,et al.  A Sulfilimine Bond Identified in Collagen IV , 2009, Science.

[112]  G. Bishop,et al.  Roles of the TRAF2/3 Binding Site in Differential B Cell Signaling by CD40 and Its Viral Oncogenic Mimic, LMP11 , 2009, The Journal of Immunology.

[113]  A. Scarpa,et al.  An integrated humoral and cellular response is elicited in pancreatic cancer by α‐enolase, a novel pancreatic ductal adenocarcinoma‐associated antigen , 2009, International journal of cancer.

[114]  M. Pfreundschuh,et al.  A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS , 2009, International journal of cancer.

[115]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[116]  Yusuke Suzuki,et al.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. , 2009, The Journal of clinical investigation.

[117]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[118]  H. Wardemann,et al.  Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. , 2008, Immunity.

[119]  Xiao-Jie Yan,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. , 2007 .

[120]  Hedda Wardemann,et al.  B-cell tolerance checkpoints in health and autoimmunity. , 2008, Current opinion in immunology.

[121]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[122]  E. Meffre,et al.  Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation , 2008, Molecular medicine.

[123]  A. Ham,et al.  A Role for Collagen IV Cross-links in Conferring Immune Privilege to the Goodpasture Autoantigen , 2008, Journal of Biological Chemistry.

[124]  R. Küppers,et al.  EBV transformation overrides gene expression patterns of B cell differentiation stages. , 2008, Molecular immunology.

[125]  D. Rossi,et al.  Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia , 2008, Haematologica.

[126]  Robert M. Plenge,et al.  Defining the Role of the MHC in Autoimmunity: A Review and Pooled Analysis , 2008, PLoS genetics.

[127]  R. Rosenquist,et al.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.

[128]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[129]  R. Fischer,et al.  Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin , 2008, Journal of Neuroimmunology.

[130]  B. Hudson,et al.  Structural basis for the crypticity of B cell epitopes of the Goodpasture autoantigen: The role of novel collagen IV crosslinks , 2008 .

[131]  W. Hammerschmidt,et al.  Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. , 2007, Blood.

[132]  P. Concannon,et al.  Genetic Variation in PTPN22 Corresponds to Altered Function of T and B Lymphocytes1 , 2007, The Journal of Immunology.

[133]  M. Nussenzweig,et al.  A role for AID in chromosome translocations between c-myc and the IgH variable region , 2007, The Journal of experimental medicine.

[134]  C. Cunningham-Rundles,et al.  CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance , 2007, The Journal of experimental medicine.

[135]  J. Bergquist,et al.  Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity , 2007, European journal of immunology.

[136]  Nikolaos Laoutaris,et al.  Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. , 2006, Blood.

[137]  David G. Schatz,et al.  Targeting of somatic hypermutation , 2006, Nature Reviews Immunology.

[138]  D. de Jong,et al.  Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions , 2006, The Journal of pathology.

[139]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[140]  E. Jaffe,et al.  IgD Positive L&H Cells Identify a Unique Subset of Nodular Lymphocyte Predominant Hodgkin Lymphoma , 2006, The American journal of surgical pathology.

[141]  L. Guilherme,et al.  Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease , 2006, Autoimmunity.

[142]  H. Stein,et al.  Molecular analysis of immunoglobulin genes in primary intraocular lymphoma. , 2005, Investigative ophthalmology & visual science.

[143]  W. Klapper,et al.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.

[144]  E. Meffre,et al.  Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. , 2005, The Journal of clinical investigation.

[145]  E. Meffre,et al.  Impaired early B cell tolerance in patients with rheumatoid arthritis , 2005, The Journal of Experimental Medicine.

[146]  K. Büssow,et al.  Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. , 2005, The Journal of clinical investigation.

[147]  D. de Jong,et al.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity , 2005, The Journal of experimental medicine.

[148]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[149]  V. Pascual,et al.  Defective B cell tolerance checkpoints in systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[150]  A. Moormann,et al.  Endemic Burkitt's lymphoma: a polymicrobial disease? , 2005, Nature Reviews Microbiology.

[151]  Ryan T. Phan,et al.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells , 2004, Nature.

[152]  F. Stevenson,et al.  Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. , 2004, Blood.

[153]  T. Jacks,et al.  Defective apoptosis and B‐cell lymphomas in mice with p53 point mutation at Ser 23 , 2004, The EMBO journal.

[154]  Steven L. Allen,et al.  Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia , 2004, The Journal of experimental medicine.

[155]  J. Cyster,et al.  Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.

[156]  Karen Leroy,et al.  Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. , 2004, Blood.

[157]  R. Pelanda,et al.  Receptor editing is the main mechanism of B cell tolerance toward membrane antigens , 2004, Nature Immunology.

[158]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[159]  J. Kutok,et al.  B cell receptor signal strength determines B cell fate , 2004, Nature Immunology.

[160]  N. Chiorazzi,et al.  B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. , 2003, Annual review of immunology.

[161]  L. Staudt,et al.  Gene Expression Profiling of Diffuse Large B-Cell Lymphoma , 2003, Leukemia & lymphoma.

[162]  H. Müller-Hermelink,et al.  VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. , 2003, Blood.

[163]  K. Calame,et al.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.

[164]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[165]  P. Baeuerle,et al.  Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. , 2003, International immunology.

[166]  D. Strickland,et al.  Low density lipoprotein receptor–related protein is a calreticulin coreceptor that signals focal adhesion disassembly , 2003, The Journal of cell biology.

[167]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[168]  B. Sander,et al.  Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. , 2003, Blood.

[169]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[170]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[171]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[172]  S. Levy,et al.  The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. , 2001, Blood.

[173]  D. Thorley-Lawson,et al.  Epstein-Barr virus: exploiting the immune system , 2001, Nature Reviews Immunology.

[174]  Riccardo Dalla-Favera,et al.  Mechanisms of chromosomal translocations in B cell lymphomas , 2001, Oncogene.

[175]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[176]  A. Fischer,et al.  Artemis, a Novel DNA Double-Strand Break Repair/V(D)J Recombination Protein, Is Mutated in Human Severe Combined Immune Deficiency , 2001, Cell.

[177]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[178]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[179]  A. Fischer,et al.  Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2) , 2000, Cell.

[180]  M. Wener,et al.  SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. , 2000, Arthritis and rheumatism.

[181]  G. Pruijn,et al.  Citrullination: a small change for a protein with great consequences for rheumatoid arthritis , 2000, Arthritis research.

[182]  A. Soley,et al.  Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. , 2000, Arthritis and rheumatism.

[183]  P. Roepstorff,et al.  The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease Is Focused on a Single Deamidated Glutamine Targeted by Tissue Transglutaminase , 2000, The Journal of experimental medicine.

[184]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[185]  F. Cavalli,et al.  Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. , 2000, Human pathology.

[186]  G. Reifenberger,et al.  Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. , 1999, The American journal of pathology.

[187]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[188]  D. Ellison,et al.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. , 1999, Blood.

[189]  L. Pasqualucci,et al.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[190]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[191]  W. Hammerschmidt,et al.  Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.

[192]  E. Cesarman,et al.  Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. , 1997, Blood.

[193]  P. Schur,et al.  Proteins Phosphorylated during Stress-induced Apoptosis Are Common Targets for Autoantibody Production in Patients with Systemic Lupus Erythematosus , 1997, The Journal of experimental medicine.

[194]  R. Flavell,et al.  Expansion or Elimination of B Cells In Vivo: Dual Roles for CD40- and Fas (CD95)-Ligands Modulated by the B Cell Antigen Receptor , 1996, Cell.

[195]  K. Rajewsky,et al.  Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells , 1996, The Journal of experimental medicine.

[196]  K. Rajewsky Clonal selection and learning in the antibody system , 1996, Nature.

[197]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[198]  R. Hughes,et al.  Campylobacter jejuni infection and Guillain-Barré syndrome. , 1995, The New England journal of medicine.

[199]  Mark M. Davis,et al.  CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells , 1995, Nature.

[200]  F. Cavalli,et al.  Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue , 1995, Annals of Internal Medicine.

[201]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[202]  R Fischer,et al.  Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[203]  R. Warnke,et al.  Helicobacter pylori infection and gastric lymphoma. , 1994, The New England journal of medicine.

[204]  M. Farquhar,et al.  Functional domains of the receptor-associated protein (RAP). , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[205]  T. C. Diss,et al.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori , 1993, The Lancet.

[206]  T. Komori,et al.  Lack of N regions in antigen receptor variable region genes of TdT-deficient lymphocytes. , 1993, Science.

[207]  C. Benoist,et al.  Mice lacking TdT: mature animals with an immature lymphocyte repertoire. , 1993, Science.

[208]  G. Ratti,et al.  Analysis of HLA DP, DQ, and DR alleles in adult Italian rheumatoid arthritis patients. , 1992, Human immunology.

[209]  D. Strickland,et al.  A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. , 1992, The Journal of biological chemistry.

[210]  P. Isaacson,et al.  L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction. , 1991, The American journal of pathology.

[211]  P. Isaacson,et al.  Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma , 1991, The Lancet.

[212]  M. Brown,et al.  39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. , 1991, The Journal of biological chemistry.

[213]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[214]  R. Hardy,et al.  Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice , 1991, Nature.

[215]  S. Swerdlow,et al.  Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. , 1990, Blood.

[216]  J. Binet,et al.  Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. , 1990, Blood.

[217]  D. Schatz,et al.  RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. , 1990, Science.

[218]  D. Nemazee,et al.  Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes , 1989, Nature.

[219]  S. Smith‐Gill,et al.  Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice , 1988, Nature.

[220]  Lawrence Steinman,et al.  T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis , 1986, Nature.

[221]  P. Möller,et al.  The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. , 1986, Immunology.

[222]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[223]  T. Lister,et al.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. , 1983, The American journal of pathology.

[224]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.

[225]  S. Tonegawa,et al.  Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[226]  R. Schwartz,et al.  Editorial: Leukemia and Auto-immunization—Some Possible Relationships , 1959 .

[227]  B. Healy,et al.  ACTRIMS 2019 - Late Breaking News Posters , 2019, Multiple Sclerosis Journal.

[228]  C. Brennan,et al.  Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. , 2017, Cancer discovery.

[229]  D. Calado,et al.  Germinal Centers , 2017, Methods in Molecular Biology.

[230]  R. Advani,et al.  Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision of the World Health Organization classi fi cation of lymphoid neoplasms , 2016 .

[231]  F. Toledo,et al.  First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[232]  G. Ricken,et al.  PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). , 2014, Clinical neuropathology.

[233]  K. Basso,et al.  BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. , 2010, Advances in immunology.

[234]  M. Pfreundschuh,et al.  Autosomal-dominant inheritance of hyperphosphorylated paratarg-7. , 2010, The Lancet. Oncology.

[235]  S. Smith‐Gill,et al.  Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. , 2009, Journal of immunology.

[236]  L. Pasqualucci,et al.  AID is required for germinal center–derived lymphomagenesis , 2008, Nature Genetics.

[237]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[238]  P. Möller,et al.  Primary mediastinal clear cell lymphoma , 2004, Virchows Archiv A.

[239]  O. Lortholary,et al.  Immunoproliferative small intestinal disease associated with Campylobacter jejuni. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[240]  F. V. D. van den Hoogen,et al.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. , 1998, The Journal of clinical investigation.

[241]  É.,et al.  Genotypic Characterization of Centrocytic Lymphoma : Frequent Rearrangement of the Chromosome 11 bcl-1 Locus , 2022 .